Appointments

866.588.2264

Submit a Form

Questions

866.588.2264

Submit a Form

Expand Content

Clinical Trials

Huntington's Disease Clinical Trials

Refer to the questions below to learn more about our current Huntington's Disease clinical trials.
Do you or a family member have Huntington's Disease (HD) ?

Cleveland Clinic is conducting a clinical research study to collect information and biological samples from HD patients and their family members to learn more about HD and to try to find new treatments for the disease.

Approximately 15,000 people are anticipated in this trial that is being conducted at approximately 200 research centers across the 30 countries.

Cleveland Clinic Main Campus (Cleveland, OH) and Cleveland Clinic Lou Ruvo Center for Brain Health (Las Vegas, NV) are participating in this research study.

The study involves yearly office visits with a neurologist and research personnel.

If you are interested in learning more about this trial, please contact study coordinator Suzanne Mazhuvanchery at 216.445.5637 or email cnrresearchreferrals@ccf.org and reference study: Enroll-HD.

You can also find additional information on this trial at clinicaltrials.gov:

Parkinson's Disease Clinical Trials

Refer to the questions below to learn more about our current Parkinson's Disease clinical trials.

Do you have Parkinson’s disease (PD) & experience involuntary movements or “wiggling” typical for levodopa-induced dyskinesia (LID)?

The Cleveland Clinic Main Campus is conducting a clinical research study to determine the effectiveness of an investigational drug, Amantadine HCl Extended Release, to decrease LID in PD patients already on levodopa and other PD medications.

Approximately 120 are being recruited for this trial – 4 at the Cleveland Clinic Main Campus.

The study involves 11 visits to the Cleveland Clinic Main Campus over a span of 26 weeks.

Main Inclusion Criteria

  • 30-85 years of age with Parkinson’s disease experiencing levodopa induced dyskinesia
  • Currently on stable dose of all medications including levodopa dosage no less than 3 times daily

Main Exclusion Criteria

  • Currently taking Amantadine (must discontinue for 30 days in order to screen for trial)
  • History of PD-related surgery
  • History of other neurological disease, sensory impairments or significant hallucinations or any other clinically significant issues
  • History of substance abuse, seizure, stroke or TIA within 2 years prior to screening

If you are interested in learning more about this trial, please contact study coordinator Alexandria Wyant at 216.444.1179 3 or email wyanta@ccf.org and reference study: ADAMAS 301.

You can also find additional information on this trial at clinicaltrials.gov:

Are you over the age of 60 with a reduced smell but do NOT have Parkinson's Disease (PD)?

Cleveland Clinic's Main Campus is working with The Michael J Fox Foundation on a clinical research study called The Parkinson’s Progression Marker Initiative (PPMI). The goal of PPMI is to identify and assess biomarkers in people who are at risk to develop PD as well as those with typical PD symptoms. The PPMI project has various sub-studies, including one looking for non-PD patients with a reduced sense of smell.

While most people with a reduced sense of smell will not develop PD, the majority of PD patients do have reduced sense of smell. This loss of smell often begins several years prior to the onset of motor symptoms like tremor or stiffness.

You qualify to participate in this PPMI sub-study if you are over the age of 60 with a reduced sense of smell and no PD diagnosis.

The study involves up to 48 months of participation. There are approximately six visits in the first year and then a visit every 6 months until completion.

If you are interested in learning more about this trial, please contact study coordinator Jennifer Mule at 216.444.1134 or email cnrresearchreferrals@ccf.org and reference study: PPMI.

You can also find additional information on this trial at clinicaltrials.gov:

Do you experience slowness, stiffness, or tremors? Have 2+ OFF hours a day? All while taking medication for Parkinson's Disease (PD) ?

The Cleveland Clinic Main Campus is conducting a clinical research study to determine the effectiveness of an investigational drug, Istradefylline, to decrease OFF time in PD patients already on levodopa and supportive PD medications.

Approximately 600 are being recruited for this trial – 8 at the Cleveland Clinic Main Campus.

The study involves 7 visits to the Cleveland Clinic Main Campus over a span of 18 weeks.

Main Inclusion Criteria

  • At least 30 years of age with moderate to severe Parkinson’s Disease and on levodopa therapy for at least one year with continued benefit
  • Currently taking levodopa/carbidopa with levodopa dosage of at least 400mg
  • Currently taking a secondary Parkinson’s Disease medication ( ex. Mirapex, Azilect, etc.)
  • At least 2 hours OFF time
  • Levodopa-induced dyskinesia

Main Exclusion Criteria

  • Currently treated with apomorphine and/or dopamine receptor antagonists or direct gastrointestinal levodopa infusion
  • Currently taking CYP3A4 inhibitors or CYP3A4 inducers (see attached sheet)
  • Experiencing sleep attacks
  • Undergone DBS

If you are interested in learning more about this trial, please contact study coordinator Suzanne Mazhuvanchery at 216.445.5637 or email mazhuvs@ccf.org and reference study: Kyowa

You can also find additional information on this trial at clinicaltrials.gov:

Do you have Parkinson's Disease (PD) and are considering deep brain stimulation (DBS) as a treatment option?

Cleveland Clinic Main Campus is recruiting for a clinical research study that being done to evaluate the safety and effectiveness of Boston Scientific’s implantable DBS system in advanced PD patients with levodopa-responsive PD that is not being adequately controlled by medication. The goal of this system is to improve the number of waking hours per day with good symptom control and no troublesome dyskinesia (involuntary movements).

Approximately 310 PD patients are being recruited for this trial with approximately ten (10) anticipated at the Cleveland Clinic Main Campus.

The study involves approximately 12 scheduled visits to the Cleveland Clinic Main Campus during Year 1with yearly visits through Year 5.

Main Inclusion Criteria (patients who may be eligible to participate)

  • Between the ages of 22-75
  • Diagnosed with PD at least five (5) years ago
  • Have symptoms of resting tremor (trembling or shaking), rigidity (stiffness) or bradykinesia (slowness of movement)
  • Willing to travel to CCF main campus for frequent visits

Main Exclusion Criteria (patients who may not be eligible to participate)

  • Ay medical or neurological condition that puts you at surgical risk
  • Any significant psychiatric condition
  • Current substance abuse

If you are interested in learning more about this trial, please contact study coordinator Alexandria Wyant at 216.444.1179. or email cnrresearchreferrals@ccf.org and reference study: INTREPID

You can also find additional information on this trial at clinicaltrials.gov:

You can also download our flyer below.

Intrepid